Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1986 1
1988 1
1989 1
1990 1
1991 3
1993 2
1994 1
1995 4
1996 1
1997 3
1998 7
1999 4
2000 10
2001 9
2002 14
2003 11
2004 10
2005 15
2006 21
2007 25
2008 37
2009 58
2010 49
2011 55
2012 70
2013 80
2014 87
2015 112
2016 117
2017 150
2018 194
2019 177
2020 186
2021 240
2022 294
2023 68
Text availability
Article attribute
Article type
Publication date

Search Results

1,889 results
Results by year
Filters applied: . Clear all
Page 1
Molecularly defined and functionally distinct cholinergic subnetworks.
Li X, Yu H, Zhang B, Li L, Chen W, Yu Q, Huang X, Ke X, Wang Y, Jing W, Du H, Li H, Zhang T, Liu L, Zhu LQ, Lu Y. Li X, et al. Among authors: ke x. Neuron. 2022 Nov 16;110(22):3774-3788.e7. doi: 10.1016/j.neuron.2022.08.025. Epub 2022 Sep 20. Neuron. 2022. PMID: 36130594
PINK1-mediated Drp1S616 phosphorylation modulates synaptic development and plasticity via promoting mitochondrial fission.
Gao Q, Tian R, Han H, Slone J, Wang C, Ke X, Zhang T, Li X, He Y, Liao P, Wang F, Chen Y, Fu S, Zhang K, Zeng F, Yang Y, Li Z, Tan J, Li J, Lu Y, Huang T, Hu Z, Zhang Z. Gao Q, et al. Among authors: ke x. Signal Transduct Target Ther. 2022 Apr 15;7(1):103. doi: 10.1038/s41392-022-00933-z. Signal Transduct Target Ther. 2022. PMID: 35422062 Free PMC article.
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.
Opat S, Tedeschi A, Linton K, McKay P, Hu B, Chan H, Jin J, Sobieraj-Teague M, Zinzani PL, Coleman M, Thieblemont C, Browett P, Ke X, Sun M, Marcus R, Portell CA, Ardeshna K, Bijou F, Walker P, Hawkes EA, Mapp S, Ho SJ, Talaulikar D, Zhou KS, Co M, Li X, Zhou W, Cappellini M, Tankersley C, Huang J, Trotman J. Opat S, et al. Among authors: ke x. Clin Cancer Res. 2021 Dec 1;27(23):6323-6332. doi: 10.1158/1078-0432.CCR-21-1704. Epub 2021 Sep 15. Clin Cancer Res. 2021. PMID: 34526366 Free PMC article.
1,889 results